OncologyTube Professional - Patients Click Here
287,515 video views
Loading........
Description: In this video, Andrew Armstrong, MD, from Duke University, Durham, NC, talks about the potential of the PROSPER (NCT02003924) and SPARTAN (NCT01946204) Phase III trials for nonmetastatic castration-re...
01:07
In this video, Andrew Armstrong, MD, from Duke University, Durham, NC, talks about the potential of the PROSPER (NCT02003924) and SPARTAN (NCT01946204) Phase III trials for nonmetastatic castration-resi​stant prostate cancer. From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, D...
by:VJOncology | 111 views
01:44
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrew Armstrong, MD, from Duke University, Durham, NC, highlights the need for novel therapies targeting plasticity pathways in particular, in order to treat bone metastases in patients with prostate cancer. Dr Armstrong also...
by:VJOncology | 89 views
03:27
Bone metastases are present in the majority of patients with prostate cancer and are the main cause of mortality in these patients. Here, Andrew Armstrong, MD, from Duke University, Durham, NC, discusses the role of osteomimicry in the formation of bone metastases, and the challenges concerning thei...
by:VJOncology | 103 views
01:07
Speaking from the 2018 Genitourinary Cancers Symposium in San Francisco, CA, Peter Black, MD, of the University of British Columbia, Vancouver, CA, outlines the development of systemic therapy for non-muscle invasive bladder cancer.
by:VJOncology | 76 views
02:33
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, introduces the key trials in progress at her center, including a treatment allocation study for patients with muscle-invasive localized bladder cancer, whi...
by:VJOncology | 15 views
03:10
Here, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, speaks at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, about how the outcome of patients with renal cell carcinoma (RCC) could potentially be improved, with promising emerging data on novel therapies. Prof. Montorsi speaks about his experie...
by:VJOncology | 20 views
02:15
Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC, outlines the changing landscape of kidney cancer, explaining the therapies at the forefront of the field right now. Dr Atkins highlights immuno-oncology combinations, mentioning a number of checkpoint inhi...
by:VJOncology | 12 views
03:03
At the Genitourinary Cancers Symposium 2018 in San Francisco, CA, recent therapeutic developments for renal cell carcinoma (RCC) were discussed by Jeanny Aragon-Ching, MD, FACP, of Inova Schar Cancer Institute, Falls Church, VA. She spoke about the changes in practice and therapy, highlighting the r...
by:VJOncology | 6 views
01:51
BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some patients continue to have persistant high-grade disease long after treatment, prompting the development of new drugs such as atezolizumab. In this video, Peter Black...
by:VJOncology | 11 views
03:29
Michael Atkins, MD, of Georgetown University, Washington DC, outlines the results of the study of VEGF inhibitor axitinib in combination with pembrolizumab for the first-line treatment of advanced renal cell cancer (NCT02133742). Dr Atkins goes onto explain the next steps required for this result to...
by:VJOncology | 11 views

About VJOncology
Description: The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of solid tumors. Our goal is to expedite learning through the sharing of new data and expert opinion, and to rapidly disseminate the latest news and information to healthcare professionals, worldwide, on a range of innovative digital media – including video and blog formats. VJOncology content will be led by an editorial board of highly respected thought leaders with a combined expertise that spans the spectrum of solid tumors. All content will be created and published under the guidance of this board of world-leading experts.

Links
Channel Url: